BR112022014414A2 - Produção de hmo - Google Patents

Produção de hmo

Info

Publication number
BR112022014414A2
BR112022014414A2 BR112022014414A BR112022014414A BR112022014414A2 BR 112022014414 A2 BR112022014414 A2 BR 112022014414A2 BR 112022014414 A BR112022014414 A BR 112022014414A BR 112022014414 A BR112022014414 A BR 112022014414A BR 112022014414 A2 BR112022014414 A2 BR 112022014414A2
Authority
BR
Brazil
Prior art keywords
hmo
production
oligosaccharide
hmo production
producing
Prior art date
Application number
BR112022014414A
Other languages
English (en)
Inventor
Pedersen Margit
Papadakis Manos
Bych Kampmann Katrine
Original Assignee
Glycom As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom As filed Critical Glycom As
Publication of BR112022014414A2 publication Critical patent/BR112022014414A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01065—3-Galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase (2.4.1.65), i.e. alpha-1-3 fucosyltransferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01146—Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase (2.4.1.146)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PRODUÇÃO DE HMO. O presente conceito inventivo se refere a uma célula geneticamente modificada habilitada para a produção de um oligossacarídeo, de um modo preferido, um HMO, compreendendo um nucleico recombinante que codifica uma proteína transportadora putativa da superfamília MFS; e métodos que utilizam a referida célula para a produção de oligossacarídeo(s), de um modo preferido um HMO.
BR112022014414A 2020-01-23 2021-01-22 Produção de hmo BR112022014414A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA202000085 2020-01-23
DKPA202000833 2020-07-13
PCT/EP2021/051473 WO2021148615A1 (en) 2020-01-23 2021-01-22 Hmo production

Publications (1)

Publication Number Publication Date
BR112022014414A2 true BR112022014414A2 (pt) 2022-09-13

Family

ID=74556858

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014414A BR112022014414A2 (pt) 2020-01-23 2021-01-22 Produção de hmo

Country Status (7)

Country Link
US (1) US20230193335A1 (pt)
EP (1) EP4093749A1 (pt)
JP (1) JP2023511527A (pt)
CN (1) CN114981290A (pt)
AU (1) AU2021209394A1 (pt)
BR (1) BR112022014414A2 (pt)
WO (1) WO2021148615A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK180952B1 (en) * 2020-12-22 2022-08-10 Glycom As A dfl-producing strain
JP2024505126A (ja) 2021-01-22 2024-02-05 グリコム・アクティーゼルスカブ シアル酸付加ｈｍｏの産生における新規の主要ファシリテータースーパーファミリー（ｍｆｓ）タンパク質（ｆｒｅｄ）
DK181497B1 (en) * 2021-05-17 2024-03-12 Dsm Ip Assets Bv ENHANCING FORMATION OF THE HMOS LNT AND/OR LNnT BY MODIFYING LACTOSE IMPORT IN THE CELL
DK202170552A1 (en) 2021-11-11 2023-09-01 Dsm Ip Assets Bv Combined fermentation process for producing one or more human milk oligosaccharide(s) (hmo(s))
WO2023166035A2 (en) 2022-03-02 2023-09-07 Dsm Ip Assets B.V. New sialyltransferases for in vivo synthesis of 3'sl and 6'sl
DK181319B1 (en) 2022-03-02 2023-08-10 Dsm Ip Assets Bv Genetically engineered cells and methods comprising use of a sialyltransferase for in vivo synthesis of 3’sl
DK202270078A1 (en) 2022-03-02 2023-12-04 Dsm Ip Assets Bv New sialyltransferases for in vivo synthesis of lst-a
WO2023209098A1 (en) 2022-04-29 2023-11-02 Dsm Ip Assets B.V. Hmo producing microorganism with increased robustness towards glucose gradients
DK202200561A1 (en) * 2022-06-13 2024-02-14 Dsm Ip Assets Bv Sigma factor modifications for biosynthetic production
DK202200689A1 (en) 2022-07-15 2024-02-27 Dsm Ip Assets Bv New fucosyltransferases for in vivo synthesis of lnfp-iii
WO2024042235A1 (en) 2022-08-25 2024-02-29 Dsm Ip Assets B.V. Hybrid method for producing complex hmos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2517602C2 (ru) * 2009-06-08 2014-05-27 Йенневайн Биотехнологи Гмбх Синтез нмо
CA3098403C (en) 2011-02-16 2022-05-10 Glycosyn LLC Biosynthesis of human milk oligosaccharides in engineered bacteria
DE202015009782U1 (de) 2014-06-11 2020-02-10 Glycom A/S Trennung von 2'-O-Fucosyllactose aus Fermentationsbrühe
JP6737788B2 (ja) 2014-09-09 2020-08-12 グリコシン リミテッド ライアビリティー カンパニー フコシル化オリゴ糖の生産において使用するためのα（１，３）フコシルトランスフェラーゼ
PL3233875T3 (pl) 2014-12-16 2023-01-23 Glycom A/S Oddzielanie 2’-FL z bulionu fermentacyjnego
EP3141610A1 (en) * 2015-09-12 2017-03-15 Jennewein Biotechnologie GmbH Production of human milk oligosaccharides in microbial hosts with engineered import / export
EP3426670A4 (en) 2016-03-07 2019-11-13 Glycom A/S SEPARATION OF OLIGOSACCHARIDES FROM A FERMENTATION BROTH
US11312741B2 (en) 2016-04-19 2022-04-26 Glycom A/S Separation of oligosaccharides from fermentation broth
DK3315610T3 (da) * 2016-10-29 2021-03-08 Jennewein Biotechnologie Gmbh Fremgangsmåde til fremstilling af fucosylerede oligosaccharider
EP3728596A4 (en) 2017-12-21 2021-08-25 Glycom A/S CONSTRUCTION OF NUCLEIC ACID ALLOWING THE EXPRESSION OF A GENE IN VITRO AND IN VIVO
US20190323052A1 (en) 2018-04-23 2019-10-24 Dupont Nutrition Biosciences Aps Increasing export of 2? fucosyllactose from microbial cells through the expression of a heterologous nucleic acid
US20190323053A1 (en) 2018-04-23 2019-10-24 Dupont Nutrition Biosciences Aps Increasing activity of 2? fucosyllactose transporters endogenous to microbial cells

Also Published As

Publication number Publication date
US20230193335A1 (en) 2023-06-22
WO2021148615A1 (en) 2021-07-29
JP2023511527A (ja) 2023-03-20
EP4093749A1 (en) 2022-11-30
CN114981290A (zh) 2022-08-30
AU2021209394A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
BR112022014414A2 (pt) Produção de hmo
BR112022014423A2 (pt) Produção de hmo
BR112022014420A2 (pt) Produção de hmo
MX2019004867A (es) Proceso mejorado para la produccion de oligosacaridos fucosilados.
BR112022014367A2 (pt) Produção de hmo
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
BR112022015628A2 (pt) Vacina de sars-cov-2
WO2008028686A3 (en) Use of human cells of myeloid leukaemia origin for expression of antibodies
BR112022011904A2 (pt) Produção de oligossacarídeo sialilado em células hospedeiras
BRPI0514870A (pt) sistemas e métodos para a produção de proteìna
CL2016001134A1 (es) Celula t o celula asesina natural (nk) que expresa dos receptores de antigeno quimerico (car), donde un car comprende un endodominio activador y el otro un dominio inhibitorio de proteina tirosina fosfatasa que contiene el dominio src (sh2); acido nucleico; vector; metodo de produccion; composicion; uso para preparar medicamento.
NZ597129A (en) Hmo synthesis
AR087433A1 (es) Analogos de insulina n-glicosilados
BR112012009886A2 (pt) célula, e, método para produzir uma proteína recombinante em uma célula hospedeira
BRPI0515428A (pt) terapia por injeção ao tumor de células dendrìticas (dcti)
BR112021023218A2 (pt) Polipeptídeos sintase de canabinoide otimizados
BR112016010340A2 (pt) novos métodos para se produzir tert ativa
ES2721179T3 (es) Composiciones cosméticas y farmacéuticas a base de líquido de incubación de pescado
BR112014029866A2 (pt) controle de fratura de fusão em tubulação de resina bimodal
BR112022000394A2 (pt) Produção de fucosilactose em células hospedeiras
BR112012013034A2 (pt) métodos e aparelhos para segregação de partículas, incluindo a segregação e a proliferação de células fetais e células-tronco
BR112022009836A2 (pt) Método para fornecer células imunes com função aumentada
BR112015019278A2 (pt) processo de elastografia multi-impulsional
BR112016025898A2 (pt) ?drimenol sintases e método para produzir drimenol?
BR112022002584A2 (pt) Célula de levedura, método para produzir um ou mais oligossacarídeos, composição de fermentação, método para recuperar um ou mais oligossacarídeos, método para modificar geneticamente uma célula de levedura

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]